White House Office of Science and Technology Policy Requests Information on the Regulation of Biotechnology

The White House Office of Science and Technology Policy (OSTP) recently released two Requests for Information (RFI) regarding the National Biotechnology and Biomanufacturing Initiative. The Initiative is intended to advance biotechnology and biomanufacturing for innovative solutions in a number of areas, including health, climate change, energy, food security, agriculture, and supply chain resilience. The goal of the program is to strengthen supply chains and lower prices, create sustainable products, create jobs, and spur new opportunities in agricultural communities.

The first RFI sought public input on how advances in biotechnology and biomanufacturing can help the country achieve societal goals related to health, climate change and energy, food and agricultural innovation, and resilient supply chains. Topics identified in the RFI include harnessing biotechnology and biomanufacturing R&D, identifying data gaps and collecting data on the bioeconomy, building a vibrant domestic biomanufacturing ecosystem, procuring biobased products, developing a biotechnology and biomanufacturing workforce, advancing biosafety and biosecurity, measuring the bioeconomy, and international engagement.

The second RFI focuses specifically on federal regulation of biotechnology. It requested public input on how to improve the clarity and efficiency of biotechnology product regulation. OSTP coordinated with the U.S. Environmental Protection Agency, the U.S. Food and Drug Administration, and the U.S. Department of Agriculture to develop the RFI.



CIEL Report Claims Regulation Stimulates Chemical Innovation

Chemical Regulation/Innovation:

Earlier this month, the Center for International Environmental Law (CIEL) released its report, Driving Innovation: How stronger laws help bring safer chemicals to market.  In the report, CIEL offers research showing that stronger laws foster innovation by large and small companies alike.  Among other things,CIEL cites the number of patents for alternative chemicals filed every time there’s new chemical regulation. CIEL is located in Washington, D.C. and Geneva, Switzerland.  More information about CIEL is available here.

Forbes magazine recently published an article on this same topic, citing the CIEL report among other sources.  That article is available here.

What do others think of this conclusion?